Search Results - "Ricci, Deborah S"

Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts by Lam, Hung-Ming, McMullin, Ryan, Nguyen, Holly M, Coleman, Ilsa, Gormley, Michael, Gulati, Roman, Brown, Lisha G, Holt, Sarah K, Li, Weimin, Ricci, Deborah S, Verstraeten, Karin, Thomas, Shibu, Mostaghel, Elahe A, Nelson, Peter S, Vessella, Robert L, Corey, Eva

“…To identify the molecular signature associated with abiraterone acetate (AA) response and mechanisms underlying AA resistance in castration-resistant prostate…”
Get full text

Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease by Smith, Matthew R, Thomas, Shibu, Gormley, Michael, Chowdhury, Simon, Olmos, David, Oudard, Stéphane, Feng, Felix Y, Rajpurohit, Yashoda, Urtishak, Karen, Ricci, Deborah S, Rooney, Brendan, Lopez-Gitlitz, Angela, Yu, Margaret, Wyatt, Alexander W, Li, Mark, Attard, Gerhardt, Small, Eric J

“…In the placebo-controlled SPARTAN study, apalutamide added to androgen-deprivation therapy (ADT) improved metastasis-free survival, second progression-free…”
Get full text

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer by Feng, Felix Y, Thomas, Shibu, Saad, Fred, Gormley, Michael, Yu, Margaret K, Ricci, Deborah S, Rooney, Brendan, Brookman-May, Sabine, McCarthy, Sharon, Olmos, David, Chowdhury, Simon, Hadaschik, Boris, Liu, Yang, Davicioni, Elai, Smith, Matthew R, Small, Eric J

“…There is a need to identify prognostic biomarkers to guide treatment intensification in patients with nonmetastatic castration-resistant prostate cancer…”
Get more information

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate by Attard, Gerhardt, de Bono, Johann S, Logothetis, Christopher J, Fizazi, Karim, Mukherjee, Som D, Joshua, Anthony M, Schrijvers, Dirk, van den Eertwegh, Alfons J M, Li, Weimin, Molina, Arturo, Griffin, Thomas W, Kheoh, Thian, Ricci, Deborah S, Zelinsky, Kathy, Rathkopf, Dana E, Scher, Howard I, Ryan, Charles J

“…Gene fusions leading to androgen receptor-modulated ERG overexpression occur in up to 70% of metastatic castration-resistant prostate cancers (mCRPC). We…”
Get full text

Genetic variation associated with bortezomib-induced peripheral neuropathy by Favis, Reyna, Sun, Yu, van de Velde, Helgi, Broderick, Erin, Levey, Laura, Meyers, Michael, Mulligan, George, Harousseau, Jean-Luc, Richardson, Paul G, Ricci, Deborah S

“…OBJECTIVETo develop a predictive genetic signature for the development of bortezomib-induced peripheral neuropathy (PN). METHODSTwo thousand and sixteen…”
Get full text

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma by Delforge, Michel, Terpos, Evangelos, Richardson, Paul G., Shpilberg, Ofer, Khuageva, Nuriet K., Schlag, Rudolf, Dimopoulos, Meletios A., Kropff, Martin, Spicka, Ivan, Petrucci, Maria T., Samoilova, Olga S., Mateos, Maria-Victoria, Magen-Nativ, Hila, Goldschmidt, Hartmut, Esseltine, Dixie-Lee, Ricci, Deborah S., Liu, Kevin, Deraedt, William, Cakana, Andrew, van de Velde, Helgi, San Miguel, Jesús F.

“…Objectives:  Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan–prednisone…”
Get full text

Association of detectable levels of circulating tumor DNA (ctDNA) with disease burden in prostate cancer (PC) by Attard, Gerhardt, Gormley, Michael, Urtishak, Karen, Simon, Jason S., Ricci, Deborah S., Parekh, Trilok V., Cheng, Shinta, Chi, Kim N., Smith, Matthew Raymond

“…Abstract only 5562 Background: PC is characterized by a relatively low prevalence of recurrent somatic point mutations. ctDNA is shed from PC and can be…”
Get full text

Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D) by Shen, Dong, Thomas, Shibu, Lefresne, Florence, Gormley, Michael, Urtishak, Karen, Lahaye, Marjolein, Tombal, Bertrand F., Merseburger, Axel S, Parekh, Trilok V., Ricci, Deborah S., Attard, Gerhardt

“…Abstract only 5066 Background: Somatic DRD deficiency in 15-30% of mCRPC pts have been observed and inhibition of enzyme poly ADP ribose polymerase (PARP)…”
Get full text

Abstract 776: Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN by Chi, Kim N., Thomas, Shibu, Gormley, Michael, Shen, Dong, Agarwal, Neeraj, Feng, Felix, Attard, Gerhardt, Wyatt, Alex, Ricci, Deborah S., Lopez-Gitlitz, Angela, Larsen, Julie S., Miladinovic, Branko, Chowdhury, Simon

“…Background: In TITAN, APA improved radiographic progression-free survival (rPFS), overall survival (OS), and second progression-free survival (PFS2) vs placebo…”
Get full text

Abstract 5425: Novel molecular subtypes identified in prostate cancer: Results from the SPARTAN study by Aguilar, Clemente, Gormley, Michael, Thomas, Shibu, Mainwaring, Paul N., Olmos, David, Saad, Fred, Chowdhury, Simon, Davicioni, Elai, Liu, Yang, Ricci, Deborah S., Lopez-Gitlitz, Angela, Yu, Margaret K., Smith, Matthew R., Small, Eric J., Feng, Felix

“…Background: Results from SPARTAN, a phase III placebo (PBO)-controlled study in patients (pts) with nonmetastatic castration-resistant prostate cancer…”
Get full text

Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN by Feng, Felix Y, Thomas, Shibu, Aguilar-Bonavides, Clemente, Gormley, Michael, Agarwal, Neeraj, Attard, Gerhardt, Wyatt, Alexander William, Davicioni, Elai, Ricci, Deborah S., Lopez-Gitlitz, Angela, Larsen, Julie S., Chowdhury, Simon, Chi, Kim N.

“…Abstract only 5535 Background: In TITAN, addition of APA to ADT improved radiographic progression-free survival (rPFS) and overall survival (OS) versus PBO…”
Get full text

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE) by Chi, Kim N., Rathkopf, Dana E., Attard, Gerhardt, Smith, Matthew Raymond, Efstathiou, Eleni, Olmos, David, Small, Eric Jay, Lee, Ji Youl, Ricci, Deborah S., Simon, Jason S., Zhao, Xin, Kothari, Nishi, Cheng, Shinta, Sandhu, Shahneen Kaur

“…Abstract only TPS5588 Background: Preclinical data suggest synergistic antitumor activity when the PARP inhibitor (PARPi) niraparib is combined with the…”
Get full text

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) by Chi, Kim N., Rathkopf, Dana E., Attard, Gerhardt, Smith, Matthew Raymond, Efstathiou, Eleni, Olmos, David, Small, Eric Jay, Lee, Ji Youl, Sieber, Paul R., Dunshee, Curtis, Ricci, Deborah S., Simon, Jason S., Zhao, Xin, Kothari, Nishi, Cheng, Shinta, Sandhu, Shahneen Kaur

“…Abstract only TPS257 Background: Preclinical data suggest synergistic antitumor activity when the PARP inhibitor (PARPi) niraparib is combined with the…”
Get full text

Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D) by Thomas, Shibu, Joshi, Shilpy, Shen, Dong, Knoblauch, Roland Elmar, Gormley, Michael, Wang, George C., Ricci, Deborah S., Motley, Clifford, Maki, Robert G., von Mehren, Margaret, Patel, Shreyaskumar, Demetri, George D.

“…Abstract only 11019 Background: To explore tumor genomic associations with response/resistance as potential predictive or prognostic biomarkers for T and D in…”
Get full text

A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350) by Subudhi, Sumit Kumar, Aparicio, Ana, Zurita, Amado J., Doger, Bernard, Kelly, William Kevin, Peer, Avivit, Rathkopf, Dana E., Karsh, Lawrence Ivan, Tryon, Jeffrey J., Kothari, Nishi, Zhao, Xin, Zhu, Eugene, Ricci, Deborah S., Tran, Namphuong, De Bono, Johann S.

“…Abstract only TPS5087 Background: Assessing multiple therapies in a single clinical trial can facilitate the rapid identification of new agents for the…”
Get full text

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study by Smith, Matthew Raymond, Fizazi, Karim, Sandhu, Shahneen Kaur, Kelly, William Kevin, Efstathiou, Eleni, Lara, Primo, Yu, Evan Y., George, Daniel J., Chi, Kim N., Saad, Fred, Summa, Jason, Freedman, Jamie M., Mason, Gary, Espina, Byron M., Zhu, Eugene, Ricci, Deborah S., Snyder, Linda A., Simon, Jason S., Cheng, Shinta, Scher, Howard I.

“…Abstract only 118 Background: Niraparib, a highly potent and selective poly (ADP-ribose) polymerase inhibitor (PARPi) received breakthrough designation by US…”
Get full text

Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study by Smith, Matthew R., Thomas, Shibu, Chowdhury, Simon, Olmos, David, Li, Jinhui, Mainwaring, Paul N., Oudard, Stéphane, Feng, Felix Y., Gormley, Michael, Ricci, Deborah S., Rooney, Brendan, Lopez-Gitlitz, Angela, Yu, Margaret K., Small, Eric J.

“…Introduction The next-generation AR inhibitor APA improves median metastasis-free survival by 2 yrs and second progression-free survival (PFS2; time from…”
Get full text

Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D) by Kapoor, Gurpreet, Li, Weimin, Shen, Dong, Knoblauch, Roland Elmar, Gormley, Michael, Wang, George C., Ricci, Deborah S., Smith, Michael P., Motley, Clifford, Malbrain, Sigrid, Maki, Robert G., vonMehren, Margaret, Patel, Shreyaskumar, Demetri, George D.

“…Abstract only…”
Get full text

Abstract CT129: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study by Feng, Felix, Thomas, Shibu, Gormley, Michael, Lopez-Gitlitz, Angela, Yu, Margaret K., Cheng, Shinta, Ricci, Deborah S., Rooney, Brendan, Mainwaring, Paul N., Olmos, David, Saad, Fred, Chowdhury, Simon, Hadaschik, Boris, Fishbane, Nick, Davicioni, Elai, Liu, Yang, Small, Eric J., Smith, Matthew R.

“…Background: The SPARTAN study recently demonstrated that the addition of APA to androgen deprivation therapy (ADT) improved metastasis-free survival (MFS) and…”
Get full text

PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE by Saad, Fred, Thomas, Shibu, Feng, Felix Y., Gormley, Michael, Lopez-Gitlitz, Angela, Yu, Margaret K., Cheng, Shinta, Ricci, Deborah S., Rooney, Oliver Brendan, Mainwaring, Paul N., Olmos, David, Chowdhury, Simon, Hadaschik, Boris A., Fishbane, Nick, Davicioni, Elai, Liu, Yang, Small, Eric J., Smith, Matthew R.

Get full text